Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients

Bone Marrow Transplantation

Volumn 38, Issue 7, 2006, Pages 521-525

  Hendriks, M P ^a   Blijlevens, N M A ^a   Schattenberg, A V M B ^a   Burger, D M ^a   Donnelly, J P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FUROSEMIDE; IDARUBICIN; MEROPENEM; METOCLOPRAMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BURNING SENSATION; CANDIDIASIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; JAUNDICE; LIVER TOXICITY; MALE; MENTAL DISEASE; METABOLIC ENCEPHALOPATHY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR; VEIN THROMBOSIS; WHOLE BODY RADIATION;

ADULT; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33749010355     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705481     Document Type: Article

References (17)

1. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A. report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
2. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
3. Sindhi R, LaVia MF, Paulling E, McMichael J, Burckart G, Shaw S et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation 2000; 69: 432-436.
4. Barama A, Sepandj F, Gough J, McKenna R. Correlation between Neoral 2h post-dose levels and histologic findings on surveillance biopsies. Transplant Proc 2004; 36 (2 Suppl): 465S-467S.
5. Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 2005; 18: 116-124.
6. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-1032.
7. Canadian Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156.
8. Canadian Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine micro- emulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157-166.
9. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249.
10. Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ. Monitoring of cyclosporine 2-h post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 2005; 24: 1343-1346.
11. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953-959.
12. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62.
13. Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002; 16: 378-382.
14. Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC. Pharmacokinetics of cyclosporine in bone marrow transplantation: Longitudinal characterization of drug in lipoprotein fractions. J Pharm Sci 1992; 81: 208-211.
15. Lindholm A, Ringden O, Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation 1987; 43: 680-684.
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Donnelly JP, Blijlevens NM, Schattenberg AV. Monitoring cyclosporine using blood drawn via a central venous catheter. Bone Marrow Transplant 2003; 32: 1037.